Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Non-Current Deffered Revenue (2019 - 2025)

Avidity Biosciences' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $28.7 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 24.42% year-over-year to $28.7 million; the TTM value through Dec 2025 reached $28.7 million, down 24.42%, while the annual FY2025 figure was $28.7 million, 24.42% down from the prior year.
  • Non-Current Deffered Revenue reached $28.7 million in Q4 2025 per RNA's latest filing, down from $32.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $43.4 million in Q1 2025 to a low of $1.2 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 5 years is $22.9 million, with a median of $28.7 million recorded in 2025.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 81.09% in 2022, then skyrocketed 3211.58% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $6.5 million in 2021, then crashed by 81.09% to $1.2 million in 2022, then surged by 3211.58% to $40.9 million in 2023, then fell by 7.18% to $38.0 million in 2024, then fell by 24.42% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Non-Current Deffered Revenue are $28.7 million (Q4 2025), $32.1 million (Q3 2025), and $40.0 million (Q2 2025).